Pricing and Access Archives

Blog

ISPOR 2023 Trinity Panel: Enabling Patient Access to Digital Therapeutics – The Optimal Approach?

June 21, 2023

Monica Martin de Bustamante, Sr. Partner of Trinity’s Evidence, Value, Access, and Pricing (EVAP) team, moderated an exciting conversation at ISPOR 2023 Global in Boston earlier this month. Monica spoke with Lisa Marsch, Ph.D., Benjamin Parcher, PharmD, MS, and Fulton Velez,...

Monica Martin de Bustamante, Sr. Partner of Trinity’s Evidence, Value, Access, and Pricing (EVAP) team presenting at ISPOR 2023

Blog

The Last Mega Blockbuster Drug: Goodbye Humira, Hello Future

April 21, 2023

Executive Summary Trinity’s Take Introduction As the second highest grossing drug worldwide, with $21.6 billion in global revenue and $17 billion in U.S. revenue in 2021, AbbVie’s Humira is one of the most commercially successful blockbuster therapies of all time. Humira...

Blog

Inflation Reduction Act of 2022: No Room for Negotiation

August 12, 2022

Long-awaited Medicare price negotiations look more like statuary discounts than the value-based negotiations seen in global healthcare systems; combined with expanded price increase rebates and out of pocket limits, new regulation may drive prices for new drugs up more than down....

Inflation Reduction Act Cover Image - Bills sticking out of a pill bottle

Blog

The Humira Case: Exploring the Blockbuster Ahead of United States Biosimilar Launch

July 20, 2022

Up to nine biosimilar versions of Humira (adalimumab) are expected to launch in 2023 in the United States, following settlements between AbbVie and their respective manufacturers. In contrast, biosimilar versions of adalimumab have been available in most countries [...]

A stethoscope and medicines on dollar bills

Blog

CMS Hospital Pricing Transparency: One Price Fits All?

August 2, 2021

Executive Summary: Trinity’s Take: Although the rule increases hospital pricing transparency and grants American patients a better estimate of their hospital’s costs prior to receiving care, low penalties, limited enforcement, and site of care loopholes lessen the impact of CMS’ Hospital...